| Literature DB >> 29229497 |
Christoph J Auernhammer1, Christine Spitzweg2, Martin K Angele3, Stefan Boeck4, Ashley Grossman5, Svenja Nölting2, Harun Ilhan6, Thomas Knösel7, Julia Mayerle8, Martin Reincke2, Peter Bartenstein6.
Abstract
In this Review, we discuss clinical developments and controversies in the treatment of neuroendocrine tumours (NETs) that are relevant for clinicians and clinical researchers. We describe advances in genetics, blood-based biomarkers, functional imaging, and systemic therapy of advanced NETs and discuss results of recent phase 3 studies, systemic treatment of advanced disease with peptide receptor radionuclide therapy, biotherapy, chemotherapy, and molecularly targeted therapy, and the potential role of immunotherapy in the treatment of NETs. Suggested treatment algorithms for NETs of ileal or jejunal origin and of pancreatic origin are presented.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29229497 DOI: 10.1016/S2213-8587(17)30401-1
Source DB: PubMed Journal: Lancet Diabetes Endocrinol ISSN: 2213-8587 Impact factor: 32.069